Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines

Trends in Parasitology

Volumn 29, Issue 9, 2013, Pages 431-437

  Fox, Barbara A ^a   Sanders, Kiah L ^a   Chen, Shan ^a   Bzik, David J ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Avirulent uracil auxotrophs; CD8+ T cells; IL 12p70; Immunotherapy; Toxoplasma gondii; Tumor regression

Indexed keywords

CARBAMOYL PHOSPHATE SYNTHASE (GLUTAMINE HYDROLYSING); CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME B; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYELOID DIFFERENTIATION FACTOR 88; TOXOPLASMA GONDII VACCINE; VASCULOTROPIN;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS PRESENTATION; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; INNATE IMMUNITY; MACROPHAGE; MELANOMA; MONOTHERAPY; MUTAGENESIS; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; PYRIMIDINE SYNTHESIS; REVIEW; TOXOPLASMA GONDII; TOXOPLASMOSIS; TUMOR IMMUNITY;

MUS; TOXOPLASMA; TOXOPLASMA GONDII;

EID: 84882877513     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2013.07.001     Document Type: Review

References (90)

1. Dubey J.P. The history and life cycle of Toxoplasma gondii. Toxoplasma gondii: The Model Apicomplexan Parasite: Perspectives and Methods 2007, 1-18. Elsevier. L.M. Weiss, K. Kim (Eds.).
2. Jones J.L., et al. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am. J. Epidemiol. 2001, 154:357-365.
3. Howe D.K., Sibley L.D. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J. Infect. Dis. 1995, 172:1561-1566.
4. Jones J.L., Dubey J.P. Foodborne toxoplasmosis. Clin. Infect. Dis. 2012, 55:845-851.
5. Dubey J.P., et al. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin. Microbiol. Rev. 1998, 11:267-299.
6. Denkers E.Y., et al. An inside job: hacking into JAK/STAT signaling cascades by the intracellular protozoan Toxoplasma gondii. Infect. Immun. 2012, 80:476-482.
7. Dupont C.D., et al. Immune response and immunopathology during toxoplasmosis. Sem. Immunopathol. 2012, 34:793-813.
8. Pifer R., Yarovinsky F. Innate responses to Toxoplasma gondii in mice and humans. Trends Parasitol. 2011, 27:388-393.
9. + T-cell: the critical catalyst in IL-12-mediated reversal of tumor immune suppression. Arch. Immunol. Ther. Exp. 2010, 58:399-405.
10. Facciabene A., et al. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012, 72:2162-2171.
11. + T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 2011, 17:5343-5352.
12. Lion E., et al. NK cells: key to success of DC-based cancer vaccines?. Oncologist 2012, 17:1256-1270.
13. Mellman I., et al. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
14. + T cell responses in vitro. J. Immunother. 2007, 30:75-82.
15. Curtsinger J.M., et al. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 2003, 197:1141-1151.
16. Kalinski P., et al. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 1999, 20:561-567.
17. Airoldi I., et al. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:3996-4001.
18. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
19. Hagemann T., et al. "Re-educating" tumor-associated macrophages by targeting NF-κB. J. Exp. Med. 2008, 205:1261-1268.
20. Galon J., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
21. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
22. + T cells in melanoma patients receiving interleukin 12. Cancer Res. 2000, 60:3559-3568.
23. Mantovani A., et al. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008, 371:771-783.
24. Car B.D., et al. The toxicology of interleukin-12: a review. Toxicol. Pathol. 1999, 27:58-63.
25. van Herpen C.M., et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin. Cancer Res. 2005, 11:1899-1909.
26. Pizzi T., Diaz M. Biological interactions between parasitic infections and tumoral growth. I. Effect of Toxoplasma gondii infections on the early growth phase of an ascites tumor of mice. Biologica (Santiago) 1963, 34:37-49.
27. Darani H.Y., et al. Effects of Toxoplasma gondii and Toxocara canis antigens on WEHI-164 fibrosarcoma growth in a mouse model. Korean. J. Parasitol. 2009, 47:175-177.
28. Suzuki Y., Kobayashi A. Antitumor effect of intralesional injection with formalin-fixed Toxoplasma gondii organisms on Lewis lung carcinoma in Toxoplasma-infected mice. Cancer Lett. 1985, 25:247-254.
29. + T cells and NK cells of melanoma-bearing mice]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2011, 23:301-306. (in Chinese).
30. Pyo K.H., et al. Suppressed CD31 expression in sarcoma-180 tumors after injection with Toxoplasma gondii lysate antigen in BALB/c mice. Korean J. Parasitol. 2010, 48:171-174.
31. Saito A., et al. Inhibitory effect of Toxoplasma lysate antigen on the multiplication of transplanted tumor in mice. Zentralbl. Bakteriol. 1989, 271:114-126.
32. Miyahara K., et al. Therapeutic effects of Toxoplasma lysate antigen on 20-methylcholanthrene-induced BALB/c mouse tumors. J. Vet. Med. Sci. 1992, 54:7-12.
33. Droller M.J., Remington J.S. A role for the macrophage in in vivo and in vitro resistance to murine bladder tumor cell growth. Cancer Res. 1975, 35:49-53.
34. Conley F.K. Effect of Corynebacterium parvum and chronic Toxoplasma infection on metastatic brain tumors in mice. J. Natl. Cancer Inst. 1979, 63:1237-1244.
35. Hibbs J.B., et al. Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J. Infect. Dis. 1971, 124:587-592.
36. Kim J.O., et al. Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. J. Korean Med. Sci. 2007, 22(Suppl.):S38-S46.
37. Hunter C.A., et al. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J. Immunol. 2001, 166:5878-5881.
38. Rankin E.B., et al. An essential role of Th1 responses and interferon γ in infection-mediated suppression of neoplastic growth. Can. Biol. Ther. 2003, 2:687-693.
39. Fox B.A., Bzik D.J. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature 2002, 415:926-929.
40. Gigley J.P., et al. Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication. J. Immunol. 2009, 182:1069-1078.
41. Gigley J.P., et al. Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain. Infect. Immun. 2009, 77:5380-5388.
42. Sukhumavasi W., et al. TLR adaptor MyD88 is essential for pathogen control during oral Toxoplasma gondii infection but not adaptive immunity induced by a vaccine strain of the parasite. J. Immunol. 2008, 181:3464-3473.
43. Robben P.M., et al. Production of IL-12 by macrophages infected with Toxoplasma gondii depends on the parasite genotype. J. Immunol. 2004, 172:3686-3694.
44. Zhao Y.O., et al. Disruption of the Toxoplasma gondii parasitophorous vacuole by IFNγ-inducible immunity-related GTPases (IRG proteins) triggers necrotic cell death. PLoS Pathog. 2009, 5:e1000288.
45. Shaw M.H., et al. Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-γ-dependent IL-10 reactivation. J. Immunol. 2006, 176:7263-7271.
46. + T cells. PLoS Pathog. 2010, 6:e1000815.
47. + effector subpopulations during Toxoplasma gondii infection. J. Immunol. 2008, 180:5935-5945.
48. Dzierszinski F.S., Hunter C.A. Advances in the use of genetically engineered parasites to study immunity to Toxoplasma gondii. Parasite Immunol. 2008, 30:235-244.
49. + T-cell responses to Toxoplasma gondii. Infect. Immun. 2009, 77:3894-3901.
50. A Commotion in the Blood: Life, Death, and the Immune System 1997, Henry Holt. S.K. Hall (Ed.).
51. Zhao Y., et al. Virulent Toxoplasma gondii evade immunity-related GTPase-mediated parasite vacuole disruption within primed macrophages. J. Immunol. 2009, 182:3775-3781.
52. Schreiber R.D., et al. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
53. + T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 2006, 211:214-224.
54. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9571-9576.
55. Wang J., et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 1998, 161:5516-5524.
56. Amos S.M., et al. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol. Immunother. 2011, 60:671-683.
57. Baird J.R., et al. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J. Immunol. 2013, 190:469-478.
58. + T-lymphocyte infiltration and affect tumour progression. J. Pathol. 2011, 223:347-357.
59. + T cells. Nature 2012, 486:545-548.
60. Boothroyd J.C., Dubremetz J.F. Kiss and spit: the dual roles of Toxoplasma rhoptries. Nat. Rev. Microbiol. 2008, 6:79-88.
61. Butcher B.A., et al. Toxoplasma gondii rhoptry kinase ROP16 activates STAT3 and STAT6 resulting in cytokine inhibition and arginase-1-dependent growth control. PLoS Pathog. 2011, 7:e1002236.
62. Saeij J.P., et al. Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologue. Nature 2007, 445:324-327.
63. Taylor S., et al. A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen Toxoplasma gondii. Science 2006, 314:1776-1780.
64. Jemal A., et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
65. Conejo-Garcia J.R., et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 2004, 10:950-958.
66. Coukos G., et al. Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. Adv. Exp. Med. Biol. 2007, 590:185-193.
67. Curiel T.J., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9:562-567.
68. Conejo-Garcia J.R., et al. Vascular leukocytes contribute to tumor vascularization. Blood 2005, 105:679-681.
69. Coukos G., et al. The role of dendritic cell precursors in tumour vasculogenesis. Br. J. Cancer 2005, 92:1182-1187.
70. Scarlett U.K., et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 2009, 69:7329-7337.
71. Santin A.D., et al. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol. Obstet. Invest. 2001, 51:254-261.
72. Zhang L., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.
73. Scarlett U.K., et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 2012, 209:495-506.
74. Chiang C.L., et al. Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS ONE 2011, 6:e28732.
75. Cubillos-Ruiz J.R., et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J. Clin. Invest. 2009, 119:2231-2244.
76. Roby K.F., et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000, 21:585-591.
77. Zhang L., et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 2003, 63:3403-3412.
78. Barber A., Sentman C.L. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J. Immunol. 2009, 183:2365-2372.
79. Baird J.R., et al. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res. 2013, 73:3842-3851.
80. Koshy A.A., et al. Toxoplasma co-opts host cells it does not invade. PLos Pathog. 2012, 8:e1002825.
81. Whitmarsh R.J., et al. A critical role for SOCS3 in innate resistance to Toxoplasma gondii. Cell Host Microbe 2011, 10:224-236.
82. Morgado P., et al. Toxoplasma gondii induces B7-2 expression through activation of JNK signal transduction. Infect. Immun. 2011, 79:4401-4412.
83. Lambert H., et al. Induction of dendritic cell migration upon Toxoplasma gondii infection potentiates parasite dissemination. Cell. Microbiol. 2006, 8:1611-1623.
84. Benson A., et al. Microbial infection-induced expansion of effector T cells overcomes the suppressive effects of regulatory T cells via an IL-2 deprivation mechanism. J. Immunol. 2012, 188:800-810.
85. + Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009, 31:772-786.
86. Curiel T.J., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
87. Peng D.J., et al. Regulatory T cells in human ovarian cancer. J. Oncol. 2012, 2012:345164.
88. Fox B.A., et al. Type II Toxoplasma gondii KU80 knockout strains enable functional analysis of genes required for cyst development and latent infection. Eukaryot. Cell 2011, 10:1193-1206.
89. Fox B.A., et al. Efficient gene replacements in Toxoplasma gondii strains deficient for nonhomologous end joining. Eukaryot. Cell 2009, 8:520-529.
90. Fox B.A., Bzik D.J. Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii. Infect. Immun. 2010, 78:3744-3752.